Welcome to our dedicated page for Moderna SEC filings (Ticker: MRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Moderna's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Moderna's regulatory disclosures and financial reporting.
Moderna, Inc. filed an initial statement of beneficial ownership for Michael R. McDonnell, identifying him as a director of the company. The filing does not report any equity transactions or derivative positions and serves to register his status as a reporting person with the SEC.
Moderna, Inc. is adding experienced financial executive Michael McDonnell to its Board of Directors, effective July 8, 2026. He will serve as a Class II director until the 2029 annual meeting and join the Board’s Audit Committee.
McDonnell brings more than 35 years of financial leadership, including service as Chief Financial Officer of Biogen Inc. from August 2020 to February 2025 and prior CFO roles at multiple public companies. David Rubenstein is transitioning off the Audit Committee to the Nominating and Corporate Governance Committee. McDonnell will receive compensation under Moderna’s Amended and Restated Non-Employee Director Compensation Policy, and his appointment was also announced in a press release furnished as Exhibit 99.1.
Moderna, Inc. reported that Chief Commercial Officer Banque Soria Ester received new equity awards as part of compensation. She was granted 38,364 restricted stock units, each convertible into one share of common stock. She was also granted 18,658 stock options with an exercise price of $79.76 per share.
For both awards, 25% are scheduled to vest on July 5, 2027, with the remaining portions vesting in twelve equal quarterly installments after that date. These are awards from the company and do not involve any open-market purchases or sales.
Moderna, Inc.’s Chief Financial Officer James M. Mock reported routine equity compensation activity involving restricted stock units (RSUs). On July 2, 2026, 1,452 RSUs converted into 1,452 shares of common stock on a one-for-one basis, reflecting vesting of a prior award.
To cover tax withholding obligations tied to this vesting, 703 shares of common stock were withheld at an effective price of $72.50 per share, a non-market, tax-related disposition rather than an open‑market sale. Following these transactions, Mock directly holds 66,436 shares of common stock and 1,454 RSUs, indicating he retained the majority of the vested shares as ongoing equity exposure.
Moderna, Inc. filed a Form 3 for Banque Soria Ester, who serves as Chief Commercial Officer. This is an initial statement of beneficial ownership that establishes her status as a reporting insider. The filing does not list any stock or option transactions, so it functions mainly as a baseline disclosure of her role under insider reporting rules.
Moderna, Inc. (MRNA) reported a Form 144 notice indicating securities were sold or to be sold under Rule 144 related to a stock option exercise on 06/18/2026. The filing lists 25,770 shares tied to the June 18, 2026 exercise and a separate sale of 36,759 shares on 05/08/2026, with dollar amounts shown in the filing. The transaction method for the exercise is listed as cash and the broker-dealer noted is Fidelity Brokerage Services LLC.
Moderna, Inc. president Stephen Hoge exercised stock options and sold shares in a pre-planned transaction. On June 15, 2026, he exercised options for a total of 53,336 shares of common stock at an exercise price of $19.15 per share, then sold 53,336 shares in an open-market transaction at an average price of $51.37 per share.
After these transactions, Hoge holds 1,483,848 shares of Moderna common stock directly, plus indirect holdings of 151,933 shares through a trust for his spouse and children and 4,116 shares through Valhalla, LLC. The filing notes that the sale was made under a Rule 10b5-1 trading plan adopted on November 13, 2025, indicating it was pre-scheduled.
Moderna, Inc. submitted a Form 144 notice relating to the proposed sale of 53,336 shares of Common Stock on 06/15/2026, identified as a Stock Option Exercise with cash settlement. The filing shows a prior sale by Stephen Hoge of 53,336 shares on 05/15/2026 for $2,581,462.40.
The filing lists a purchaser/recipient line for Fidelity Brokerage Services LLC and numeric values of $2,739,870.32 and 396,786,259 appearing in the excerpt; the document links the shares and exercise method to the issuer and cash settlement.
Moderna, Inc. Chief Legal Officer Shannon Thyme Klinger reported a mix of option exercises, RSU vesting, tax withholding, and a small stock sale. She exercised stock options and restricted stock units to acquire a total of 15,269 shares of common stock.
On one date, 3,471 shares of common stock were sold at $50.00 per share in an open-market transaction made under a pre-arranged Rule 10b5-1 trading plan. Separately, 5,705 shares were withheld to cover tax obligations related to RSU vesting, which is not an open-market sale.
Moderna, Inc.’s Chief Financial Officer James M. Mock reported routine equity compensation activity. On June 5, 2026, 11,798 restricted stock units converted into the same number of common shares on a one-for-one basis. To cover tax withholding obligations tied to this vesting, 5,705 common shares were withheld rather than sold on the open market. After these transactions, he directly holds 65,687 shares of common stock and 117,976 restricted stock units, reflecting ongoing equity-based compensation rather than discretionary buying or selling.